GlobeNewsWire
19 Oct 2026, 06:00 UTC · 2h ago
Impact · against what's priced in
Oculis increases the probability of success for its Licaminlimab registration trial by concentrating patients with the TNFR1 genetic variant. This strategic enrichment of the PREDICT-1 cohort reduces the clinical risk ahead of the data readout.
Scored by the NIS engine · methodology.
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Oculis has completed randomization in the PREDICT-1 registration trial for Licaminlimab, with 2/3 of the 176 enrolled patients carrying the TNFR1 genetic variant.
Newpublished 2026-10-19 06:00 UTC
So whatConcentrating ~117 patients with the positive variant increases the probability of meeting primary endpoints in the upcoming data read-out.
More positive than 94% of claims this week
Continue reading
5 related stories
Top 1 mover · tap to explore
Read next
Business Wire · 2h ago
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
11h ago
